Aug 10, 2026 04:30PM
Jul 31, 2026 12:07PM
Jun 30, 2026 08:02AM
Jun 30, 2026 08:00AM
May 11, 2026 04:23PM
Mar 31, 2026 07:06AM
Mar 31, 2026 06:40AM SCYNEXIS acquires PXL-770 drug for rare kidney disease treatment
Mar 31, 2026 06:40AM
Mar 4, 2026 04:20PM
Feb 26, 2026 08:23AM
Feb 26, 2026 08:23AM
Jan 28, 2026 08:00AM
Jan 21, 2026 08:01AM
Jan 21, 2026 08:00AM SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
Dec 22, 2025 08:02AM
Dec 22, 2025 08:00AM
Nov 19, 2025 07:00AM
Nov 17, 2025 10:16AM
Nov 17, 2025 10:15AM
Nov 5, 2025 04:20PM
Oct 28, 2025 07:14AM SCYNEXIS (SCYX) PT Lowered to $3 at Guggenheim
Oct 15, 2025 08:01AM
Oct 15, 2025 08:00AM
Sep 30, 2025 08:00AM
Sep 30, 2025 08:00AM
Sep 4, 2025 08:30AM
Aug 25, 2025 08:00AM
Aug 13, 2025 04:30PM SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
May 28, 2025 08:31AM
May 28, 2025 08:30AM
May 15, 2025 04:20PM
Apr 8, 2025 08:05AM
Apr 8, 2025 08:00AM
Mar 12, 2025 05:08PM
Dec 18, 2024 08:00AM SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Nov 6, 2024 04:30PM
Oct 10, 2024 08:00AM
Oct 3, 2024 08:00AM
Aug 27, 2024 08:00AM
Aug 8, 2024 04:30PM
Jul 23, 2024 07:02AM
Jul 23, 2024 07:00AM SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
May 8, 2024 04:30PM
Apr 30, 2024 04:05PM
Apr 9, 2024 04:05PM
Mar 28, 2024 04:01PM
Jan 30, 2024 04:05PM
Jan 29, 2024 05:15PM
Jan 29, 2024 05:15PM SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
Jan 5, 2024 09:00PM

328,143 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All